Do electrolytes help with GLP-1 constipation
Epithalon (Epitalon) Primary uses: Longevity Telomere lengthening Sleep regulation (melatonin) Anti-aging Typical dosing: 10mg per cycle 1mg daily for 10 days Cycles: Every 3-6 months Administration: Subcutaneous injection Special notes: Strong evidence for telomere lengthening Used in anti-aging protocols Well-tolerated Improves sleep regulation (pineal gland function) Thymosin Alpha-1 Primary uses: Immune system optimization Anti-viral effects Longevity Chronic illness support Typical dosing: 0.5-1mg, 2-3 times per week Duration: Ongoing or cycles Administration: Subcutaneous injection Special notes: Powerful immune modulator FDA-approved for hepatitis (Zadaxin) Well-studied safety profile Used in longevity protocols Selank Primary uses: Anxiety reduction Cognitive enhancement Immune modulation Neuroprotection Typical dosing: 250-500mcg daily Injectable or intranasal Duration: 2-4 weeks, then break Administration: Subcutaneous injection or intranasal spray Special notes: Developed in Russia Anxiolytic without sedation Improves focus and mental clarity No dependence or withdrawal Semax Primary uses: Cognitive enhancement Focus and concentration Neuroprotection Stroke recovery Typical dosing: 300-600mcg daily Injectable or intranasal Duration: 2-4 weeks, then break Administration: Subcutaneous injection or intranasal spray Special notes: Powerful nootropic Increases BDNF (brain-derived neurotrophic factor) Improves learning and memory Developed in Russia Sexual health peptides These enhance libido, arousal, and sexual function
With the right approach to Retatrutide dosing, youre giving yourself the best chance at achieving lasting results
Hypothalamic leptin signaling regulates hepatic insulin sensitivity via a neurocircuit involving the vagus nerve
Novo puts $285m into monthly GLP-1 based on Ascendis tech Novo Nordisk has partnered with Ascendis Pharma on less frequently dosed drugs for obesity and other metabolic diseases, starting with a once-monthly GLP-1 receptor agonist
Disruption of the bone remodelling equilibrium leads to skeletal diseases including osteoporosis, Pagets disease of bone, rheumatoid arthritis, as well as osteogenesis imperfecta
